Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "IPO"

139 News Found

Clariant to launch eight new high-performing excipients at the CPHI Milan 2024
News | October 03, 2024

Clariant to launch eight new high-performing excipients at the CPHI Milan 2024

Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines


Sun Pharma and Moebius Medical granted FTD to MM-II for treatment of osteoarthritis knee pain
Drug Approval | September 06, 2024

Sun Pharma and Moebius Medical granted FTD to MM-II for treatment of osteoarthritis knee pain

This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II


Caplin Point announces completion of unannounced USFDA inspection
Drug Approval | August 11, 2024

Caplin Point announces completion of unannounced USFDA inspection

The inspection was concluded with zero observations


Nephro Care India lists at 90% premium
News | July 06, 2024

Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90


Cardiological Society of India releases first Indian guidelines for dyslipidemia management
News | July 05, 2024

Cardiological Society of India releases first Indian guidelines for dyslipidemia management

Dyslipidemia is a critical risk factor for cardiovascular diseases


Ascentage Pharma closes US$ 75 million equity investment by Takeda
News | June 24, 2024

Ascentage Pharma closes US$ 75 million equity investment by Takeda

Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO


Sun Pharma and Moebius Medical present Phase 2b study on MM-II
Diagnostic Center | June 15, 2024

Sun Pharma and Moebius Medical present Phase 2b study on MM-II

There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis


Bristol Myers Squibb completes acquisition of Karuna Therapeutics
News | March 21, 2024

Bristol Myers Squibb completes acquisition of Karuna Therapeutics

KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia


Zydus receives USFDA final approval for chlorpromazine hydrochloride injection
Drug Approval | March 14, 2024

Zydus receives USFDA final approval for chlorpromazine hydrochloride injection

Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders